Forward-Looking Statements. This presentation contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to known and unknown risks, uncertainties and other important factors that may cause actual results to be materially different from the statements made herein. All statements other than statements of historical fact included in this presentation are forward-looking statements, including, but not limited to, the Company's financial re ...

Acquisition of Ask Sage - BigBear.ai announced the acquisition of Ask Sage, an advanced generative-AI platform tailored for government agencies and highly regulated industries[11, 13] - Ask Sage's ARR grew 6X from '24-'25 and currently serves 16,000 government teams[13] - Ask Sage offers a secure platform for AI use in USG/DoD, reliable data and system connectivity, a marketplace for AI-powered tools, and services for custom AI apps[26] - Synergies between Ask Sage and BigBear.ai include cross-selling, customer expansion, tech integration, and go-to-market strategies[28] Financial Highlights (Q3 2025) - The company reported a record ending cash and investments balance of $715 million[33, 34] - The company had a net positive cash and investments position of almost $575 million as of the end of Q3[34] - For the three months ended September 30, 2025, net loss was $2521 thousand, compared to a net loss of $15135 thousand for the three months ended September 30, 2024[40] - For the three months ended September 30, 2025, Adjusted EBITDA was $(9401) thousand[40] - Revenues for the three months ended September 30, 2025 were $33143 thousand with a gross margin of 22.4% and an adjusted gross margin of 27.7%[43] Strategic Focus - The company focuses on disruptive AI software for national security, smart & secure travel & trade, and dual-use platform-level AI[18, 19]

Core Insights - Ready Capital Corporation reported a GAAP loss per common share from continuing operations of $(0.13) and a distributable loss per common share of $(0.94) for the quarter ended September 30, 2025 [1][22] - The company is focused on restoring financial health through decisive exit strategies for underperforming loans and risk management of upcoming debt maturities, aiming for balance sheet stability and profitability [2] Financial Performance - The company reported LMM commercial real estate originations of $139 million and Small Business Lending loan originations of $283 million, which included $173 million of Small Business Administration 7(a) loans [6] - The book value of common stock was $10.28 per share as of September 30, 2025 [6] - The company completed two portfolio sales consisting of 217 loans with an unpaid principal balance of $758 million for net proceeds of $109 million [6] Non-GAAP Financial Information - Distributable earnings, a non-GAAP measure, is defined as net income adjusted for various unrealized gains and losses, providing greater transparency into financial performance [3][4] - The calculation of distributable earnings excludes unrealized gains and losses on mortgage-backed securities retained as part of the loan origination business, as these are considered fundamental to ongoing performance [5] Income Statement Highlights - For the three months ended September 30, 2025, the company reported net interest income before provision for loan losses of $10,520 thousand, with a net loss from continuing operations of $(16,947) thousand [22][23] - Total non-interest income was $74,914 thousand, while total non-interest expense was $74,339 thousand, resulting in a loss from continuing operations before income taxes of $(26,882) thousand [22][23] Balance Sheet Overview - As of September 30, 2025, total assets were $8,332,101 thousand, with total liabilities of $6,448,542 thousand, resulting in stockholders' equity of $1,875,198 thousand [20][21] - The company had cash and cash equivalents of $147,505 thousand and loans net of $4,360,501 thousand [20]

Company Overview - As of September 30, 2025, CareTrust REIT's real estate portfolio has grown to 390 net-leased healthcare properties across 31 states and the United Kingdom, consisting of 35,687 operating beds/units[15] - CareTrust REIT also had 23 other real estate related investments related to 143 healthcare properties across 17 states and the United Kingdom, consisting of 14,082 operating beds/units and one financing receivable related to 46 properties in one state consisting of 3,820 operating beds/units[15] - The company's total investments reached $4,812.044 million, with a current yield of 9.7%[29] Portfolio Composition - Skilled Nursing Facilities (SNF) constitute 46.9% of the total investment, amounting to $2,255.078 million with a current yield of 10.6%[29] - UK Care Homes represent 19.3% of the total investment, totaling $930.768 million with a current yield of 7.4%[29] - Multi-Service Campuses account for 10.5% of the total investment, with a value of $503.626 million and a current yield of 9.7%[29] Financial Performance - For the three months ended September 30, 2025, the company reported rental income of $104.265 million[51] - Net income attributable to CareTrust REIT, Inc for the three months ended September 30, 2025, was $74.901 million, or $0.35 per share on a diluted basis[51] - Normalized FFO attributable to CareTrust REIT, Inc for the quarter ended September 30, 2025, was $94.677 million[53] Tenant Diversification - The Ensign Group is the largest tenant, contributing 24.8% of total rent with $92.102 million[32] - The top 5 tenants account for 55.7% of total rent, amounting to $207.260 million[32]

Q3 2025 Performance - Enovis reported a net sales increase to $549 million, a +9% growth, with +7% organic growth[17,8] - Reconstructive segment sales reached $258 million, showing +12% year-over-year growth and +9% organic growth[10] - Prevention & Recovery (P&R) segment sales were $291 million, with +6% year-over-year growth and +4% organic growth[15] - Adjusted gross profit increased to $331 million, resulting in a margin of 603%, compared to $298 million and 589% respectively in Q3 2024[17] - Adjusted EBITDA was $95 million, with a margin of 173%, compared to $90 million and 179% respectively in Q3 2024[17] - Adjusted EPS increased to $075, compared to $073 in Q3 2024[17] Full Year 2025 Outlook - Enovis anticipates full year reported revenue between $224 billion and $227 billion[23] - The company projects adjusted EBITDA between $395 million and $405 million[23] - Enovis estimates adjusted EPS to be between $310 and $325[23] Strategic Actions - Enovis divested its Footcare business, which represented 48% of Prevention and Recovery and 24% of Enovis revenues, impacting Q4 2025 revenue guidance by approximately $15 million[20] - The total transaction value for the Footcare divestiture is up to $60 million, including an upfront cash payment of $45 million and milestone payments up to $15 million[22]

Financial Performance - Revenue for Q3 2025 was $20.6 million, at the high end of the $19-$21 million guidance range[7, 8] - Gross margin for Q3 2025 was 58.4%, exceeding the guidance range of 56%-58%[7, 8] - Adjusted EBITDA for Q3 2025 was $2.0 million, compared to $1.3 million in Q3 2024[7, 8] - Cash provided by operations was $6.8 million, up from ($0.3 million) in the same period last year[7] Regional Performance - APAC revenue decreased by 19.6% year-over-year, impacted by China tariffs[9] - EMEA revenue was relatively flat, down 0.6% year-over-year, influenced by macroeconomic instability[9] - Americas revenue decreased by 4.4% year-over-year, with a recovery in Pre-Clinical driven by NIH/ACA funding[9] Outlook and Strategy - The company is focused on refinancing or repaying the existing credit agreement in Q4 2025[7] - Q4 revenue is projected to range from $22.5 million to $24.5 million[17] - Q4 gross margin is expected to range from 58% to 60%[17]

Financial Performance - FY25 - Consolidated revenue reached approximately $14.5 billion, a decrease of 1% year-over-year[12] - Adjusted EBITDA remained flat year-over-year at $881 million[12] - Free cash flow was reported at $204 million[12] - The company repurchased approximately 7% of its shares outstanding, amounting to $125 million in capital return[12] Q4 FY25 Highlights - Consolidated sales increased by 4% year-over-year, reaching $3.7 billion[13] - Adjusted EBITDA for Q4 FY25 was $226 million, with a margin of 6.1%[13] - Strong free cash flow generation of $134 million was achieved during the quarter[13] FY26 Outlook - Sales are projected to be approximately $14.4 billion due to lower expected production volumes[88] - Adjusted EBITDA is expected to be around $845 million, influenced by business performance offsetting volume headwinds[88] - Free cash flow is forecasted at approximately $90 million, impacted by timing shifts and increased growth spending[88] Regional Sales Performance (Q4 FY25) - Americas sales outperformed the market by 100 bps due to favorable volume/mix[51] - EMEA sales underperformed the market by 400 bps mainly due to customer mix[51]

Core Insights - Standard BioTools Inc. reported financial results for Q3 2025, highlighting a focus on operational efficiency and cost savings initiatives aimed at achieving profitability by 2026 [3][4][7]. Financial Performance - Q3 2025 revenue from continuing operations was $19.6 million, a decrease of 11% year-over-year from $22.1 million in Q3 2024 [6][12]. - Gross margin for Q3 2025 was 48.5%, down from 54.9% in Q3 2024, while non-GAAP gross margin was 53.5%, compared to 57.3% in the same period last year [6][12]. - Operating expenses increased to $42.4 million in Q3 2025, up 9% from $38.8 million in Q3 2024, largely due to restructuring charges [6][12]. - The net loss from continuing operations for Q3 2025 was $31.7 million, compared to a net loss of $21.9 million in Q3 2024, marking a 45% increase in losses [6][12]. Operational Restructuring - The company implemented a phased operational restructuring plan expected to yield over $40 million in annualized cost savings by 2026, including a 20% reduction in workforce [4][5]. - The restructuring aims to enhance operational efficiency and align resources with long-term strategic goals, contributing to a path toward positive adjusted EBITDA in 2026 [4][5]. Cash Position and Future Outlook - As of September 30, 2025, Standard BioTools had $217 million in cash and cash equivalents, with an anticipated increase to approximately $550 million following a pending transaction with Illumina in the first half of 2026 [7][10]. - The company continues to expect full-year 2025 revenue in the range of $165 million to $175 million, with revenue from continuing operations projected between $78 million and $83 million [10]. Market Position and Strategy - Standard BioTools is positioned to expand its portfolio through strategic mergers and acquisitions, leveraging a strong balance sheet and cash reserves to drive growth and deliver long-term shareholder value [3][7].

Q3 2025 Financial Performance - Net sales decreased by $131 million, a 16% decrease year-over-year, primarily due to lower sales in North America On-Highway, Global Off-Highway, Service Parts, Support Equipment & Other, and Outside North America On-Highway end markets, partially offset by higher sales in the Defense end market and price increases on certain products[17] - Net income decreased by $63 million, a 32% decrease year-over-year, to $137 million, principally driven by lower gross profit and acquisition-related expenses[14, 17] - Adjusted EBITDA decreased by $49 million, a 16% decrease year-over-year, to $256 million, driven by lower gross profit[14, 17] - Adjusted EBITDA margin was 36.9%, a decrease of 10 bps year-over-year, remaining essentially flat despite a challenging operating environment[14, 17] - Adjusted Free Cash Flow decreased by $26 million, a 12.4% decrease year-over-year, to $184 million, driven by lower net cash provided by operating activities and higher capital expenditures[14, 18] Segment Performance - North America On-Highway net sales decreased by 28% to $327 million, principally driven by lower demand for Class 8 vocational and medium duty trucks, partially offset by price increases and market share gains for hybrid propulsion systems for transit buses[16] - Outside North America On-Highway net sales decreased by 3% to $122 million, principally driven by lower demand in Asia, partially offset by higher demand in Europe[16] - Global Off-Highway net sales decreased by 65% to $7 million, principally driven by lower demand from the energy, mining and construction sectors outside of North America[16] - Defense net sales increased by 47% to $78 million, principally driven by increased demand for Tracked vehicle applications, price increases, and the continued execution of growth initiatives[16] - Service Parts, Support Equipment & Other net sales decreased by 5% to $159 million, principally driven by lower demand for aluminum die cast components and support equipment, partially offset by price increases[16]

Financial Performance - Heritage Financial Corporation's net income for Q3 2025 was $192 million[19], with a net interest margin of 364%[19] - The company's ROAE was 852% and ROATCE was 1186% for Q3 2025[19] Adjusted ROATCE was 1216%[19] - The efficiency ratio was 633%, and the adjusted efficiency ratio was 624% for Q3 2025[19] - The company's leverage ratio was 105% and the total capital ratio was 138%[19] Loan Portfolio - Loans receivable totaled $48 billion as of September 30, 2025[19] - Real estate, rental, and leasing comprised 561% of commercial business loans by industry exposure, totaling $2122 million[46] - Nonaccrual loans to loans receivable was 037% in Q3 2025[56] Deposits - Deposits totaled $59 billion as of September 30, 2025[19] - Noninterest demand deposits were 276% of total deposits as of September 30, 2025[22] - The cost of total deposits was 137%[22] Investment Portfolio - The investment portfolio yield was 335%[86] - Investment cashflows are estimated to be $561 million through Q3 of 2028[88] M&A Activity - On September 25, 2025, Heritage Financial Corporation entered into a definitive agreement with Olympic Bancorp, Inc, which has $17 billion in assets[22, 28]